ABSTRACT
Background Different methods and formulae have been developed for different populations for estimation of GA in the first trimester of pregnancy. In this study, we develop an Indian population-specific GA dating formula and compare its performance with the previously published formulae. Finally, we evaluate the implications of the choice of dating method on preterm birth (PTB) rate. The data for this study was from the GARBH-Ini cohort, an ongoing (2015-2019) longitudinal pregnancy cohort of North Indian women to study PTB.
Methods Comparisons between USG (Hadlock) and LMP-based dating methods were made by studying the distribution of their differences by BA analysis. Population-specific dating formula for the first trimester of pregnancy (Garbhini-1 formula) was developed by constructing a regression model for GA as a non-linear function of CRL, which was then compared with published formulae by BA analysis. The PTB rate was estimated by using each of these methods and expressed as prevalence and 95% CI.
Results LMP-based method overestimates GA by three days as compared to USG (Hadlock) method with limits of agreement between -4.39 and 3.51 weeks (95% CI). CRL is the most critical parameter in estimating GA in the first trimester. No other clinical or socioeconomic parameter enumerated in the GARBH-Ini cohort study contributes to GA estimation. The GA estimated by all the formulae compared showed an agreement within a week with the uppermost and the lowermost limits of agreement (LOA) being -0.46,0.96 weeks. The estimated PTB rate across all the formulae ranged between 12.12 and 16.85% with Garbhini-1 formula estimating the least rate.
Conclusions Our study reinforces the fact that CRL-based USG method is best for estimation of GA in the first trimester and addition of clinical and demographic features does not improve its accuracy. Garbhini-1 formula developed from our population data performs at par with the existing formulae but estimates the lowest PTB rate with better precision than other formulae. The applicability of Garbhini-1 formulae for the rest of the Indian population needs to be validated in subsequent studies.
Study question
Is there a need for an Indian population-specific GA estimation model?
Which clinical and socioeconomic features affect the estimation of GA in an Indian population?
Does the choice of a GA estimating model affect the classification of PTB?
What is already known
Several first trimester GA estimation formulae have been published based on different population studies.
In India, Hadlock’s formula, based on a US population, is primarily used for GA estimation.
Reliable GA is required for accurately estimating the PTB rate in a population.
What this study adds
We have developed Indian population-specific Garbhini-1 formula for GA estimation in the first trimester.
Garbhini-1 formula performs comparably to other published formulae in estimating GA and in classifying PTB.
In the first trimester, CRL is the only feature that affects GA estimation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by an intramural grant from Initiative for Biological Systems Engineering, IIT Madras (BIO/18-19/304/ALUM/KARH). GARBH-Ini cohort study is funded by Department of Biotechnology, Government of India (BT/PR9983/MED/97/194/2013) and for some components of the biorepository by the Grand Challenges India-All Children Thriving Program (supported by the Programme Management Unit), Biotechnology Industry Research Assistance Council, Department of Biotechnology, Government of India (BIRAC/GCI/0114/03/14-ACT).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All supplementary data used in the manuscript is submitted. Primary data can be shared according to the GARBH-Ini data sharing policy which available on request.